Maduck Sean's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed Jun 4, 2025
- Accession no.
- 0000950170-25-081933
- Filed
- Jun 4, 2025
- Trade date
- Jun 2, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.58M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maduck SeanCIK 0001698310 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 2, 2025 | Common Stock | AGrant or awardAcquired | +888 | $71.68F2 | +$63,651.84 | 16,817 | Direct | |
| Jun 2, 2025 | Common Stock | AGrant or awardAcquired | +888 | $0.00 | $0 | 17,705 | Direct | |
| Jun 2, 2025 | Common Stock | AGrant or awardAcquired | +20,000 | $5.05 | +$101,000 | 37,705 | Direct | |
| Jun 2, 2025 | Common Stock | SSaleDisposed | −5,752 | $77.91F6 | −$448,138.32 | 31,953 | Direct | |
| Jun 2, 2025 | Common Stock | SSaleDisposed | −6,191 | $78.87F7 | −$488,284.17 | 25,762 | Direct | |
| Jun 2, 2025 | Common Stock | SSaleDisposed | −6,246 | $79.89F8 | −$498,992.94 | 19,516 | Direct | |
| Jun 2, 2025 | Common Stock | SSaleDisposed | −1,811 | $80.77F9 | −$146,274.47 | 17,705 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 2, 2025 | Common Stock | MOption exerciseDisposed | −20,000 | $0.00 | $0 | 61,986 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
Referenced by the price of 1 transaction in Table I.
- F6
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $77.56 to $78.515 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F7
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $78.57 to $79.5675 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F8
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.5725 to $80.535 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F9
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.585 to $81.00 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.